NeuroOne Medical Technologies (OTC:NMTC) announced that it was approved to uplist and begin trading on the Nasdaq market.
Eden Prairie, Minn.-based NeuroOne expects trading to commence today at the open of the market, with the company trading under the “NMTC” ticker, according to a news release.
The developer of surgical care options for patients suffering from neurological disorders will continue to trade on the OTC markets until trading commences on the Nasdaq.
“The team at NeuroOne has worked relentlessly for the past four years to position the company to accomplish this major milestone,” NeuroOne CEO Dave Rosa said in the release. “Nasdaq has an established reputation for being an exchange associated with emerging growth stocks and we believe our uplisting will elevate the company’s corporate profile with current and prospective investors, and the financial community as a whole.
“As the company continues to grow, we are hopeful our Nasdaq uplisting will generate even greater interest in our company from leading institutional investment firms across the broader national and international investment community. I want to also thank all of our current and past investors who were critical in helping us accomplish this critical milestone.”